Acadia (ACAD) presented yesterday at the annual JP Morgan Healthcare Conference. Not much new information was presented, just a reiteration of timelines, and current, and future clinical trials. The breakout session afterwards yielded a few questions regarding their phase 2 ADP (Alzheimer's Disease Psychosis) trial.
- The company is looking for a -3 point reduction from placebo on the hallucinations and delusions sub-scale at six weeks, as primary endpoint.
- Also at six weeks into the trial, they will be using a more broad scale, the NPI - NH (Neuropsychiatric Inventory-Nursing Home) and the CMAI-SF (Cohen Mansfield Agitation Inventory - Short Form) respectively. The NPI-NH scale encompasses behavioral as well as psychosis as one complete measure.
- At 12 weeks, they will measure cognition, functional and behavioral performance since the beginning of the trial using the ADCS - CGIC (Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change).
Bottom Line: Management did another fine job explaining the science, clinical trial updates, and timelines for 2015. Thank you for reading.
No comments:
Post a Comment